KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Other financing activities (2016 - 2025)

Historic Other financing activities for Medtronic (MDT) over the last 12 years, with Q4 2025 value amounting to -$5.0 million.

  • Medtronic's Other financing activities rose 8979.59% to -$5.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was -$55.0 million, marking a year-over-year increase of 7500.0%. This contributed to the annual value of -$184.0 million for FY2025, which is 603333.33% down from last year.
  • Medtronic's Other financing activities amounted to -$5.0 million in Q4 2025, which was up 8979.59% from $70.0 million recorded in Q3 2025.
  • Medtronic's 5-year Other financing activities high stood at $273.0 million for Q3 2022, and its period low was -$719.0 million during Q1 2023.
  • Its 5-year average for Other financing activities is -$28.3 million, with a median of -$7.0 million in 2022.
  • In the last 5 years, Medtronic's Other financing activities surged by 692500.0% in 2022 and then tumbled by 1188333.33% in 2023.
  • Quarter analysis of 5 years shows Medtronic's Other financing activities stood at -$42.0 million in 2021, then soared by 504.76% to $170.0 million in 2022, then decreased by 5.29% to $161.0 million in 2023, then crashed by 130.43% to -$49.0 million in 2024, then skyrocketed by 89.8% to -$5.0 million in 2025.
  • Its Other financing activities was -$5.0 million in Q4 2025, compared to $70.0 million in Q3 2025 and -$280.0 million in Q2 2025.